MEMORANDUM

MEMORANDUM
PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT / ATTORNEY-CLIENT PRIVILEGE
FROM: Leila Nazari, Calderwood & Harkness LLP
TO: Leonard Cross, Sylvia Hartwell, Garrett Simmons
DATE: July 28, 2022
RE: Analysis of Intercompany License Agreement for Legacy Compounds — Penterra Pharmaceuticals Corp. / Penterra Biopharma International DAC — Royalty Rate and Arm's-Length Compliance
MATTER NO.: 1018-00009
CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to analyze the intercompany license agreement (the "License Agreement") between Penterra Pharmaceuticals Corp. ("PPC") and Penterra Biopharma International DAC ("PBI") covering legacy pharmaceutical compounds — specifically, pre-2012 vintage intellectual property that was not included in the qualified cost-sharing arrangement ("CSA") between PPC and PBI — for compliance with the arm's-length standard under Section 482 of the Internal Revenue Code ("IRC") and the regulations promulgated thereunder, principally Treasury Regulation ("Treas. Reg.") § 1.482-4.
The License Agreement establishes a royalty rate of 4.5% of net sales for PBI's exploitation of the legacy compound portfolio in the non-Americas territory, defined to include the Europe, Middle East, and Africa ("EMEA") and Asia-Pacific ("APAC") regions. These legacy compounds are mature pharmaceutical products that predate the CSA effective July 1, 2012, and were neither contributed to the CSA nor covered by the platform contribution transaction ("PCT") payment made by PBI in connection with the CSA. They remain wholly owned by PPC and are licensed to PBI under the separate License Agreement at issue here.
Our preliminary conclusion is that the 4.5% royalty rate is supportable under the arm's-length standard using the comparable uncontrolled transaction ("CUT") method, which we have determined to be the best method under Treas. Reg. § 1.482-1(c) for evaluating the royalty charged in the License Agreement. The 4.5% rate falls within the interquartile range ("IQR") of 3.1% to 6.8% identified in the contemporaneous transfer pricing documentation prepared by Susan Lam, Transfer Pricing Partner at Crestfield & Associates LLP, and is proximate to the median of 4.4% — only 0.1 percentage point above the median. This positioning within the arm's-length range strongly supports the defensibility of PPC's royalty rate under the applicable legal standards.
We note, however, that the Internal Revenue Service ("IRS") examination (Exam Team LB&I-NE-TP-2022-00641, opened May 16, 2022, for tax years 2017 through 2020) is expected to challenge this royalty rate, potentially seeking to increase it substantially. Based on publicly available IRS guidance, examination trends in the pharmaceutical sector, and the scope of the initial Information Document Requests ("IDRs") issued by the IRS examination team, we anticipate that the IRS may contend that the royalty rate should be set at approximately 11.0% or higher, based on alternative CUT comparables involving growth-stage or blockbuster pharmaceutical compounds. If such an adjustment were proposed, it would result in an aggregate royalty adjustment of approximately $188.04 million across the four examination years — a significant exposure that warrants vigorous defense.
The analysis set forth below provides a comprehensive evaluation of the License Agreement's terms, the applicable legal and regulatory framework, the best method analysis supporting use of the CUT method, the comparability analysis and arm's-length range, anticipated IRS challenges and our recommended rebuttal arguments, economic substance considerations, Irish and international tax coordination issues, Tax Cuts and Jobs Act ("TCJA") implications, and penalty protection. This memorandum concludes with an overall risk assessment and recommended next steps for the defense strategy.
II. Background
A. Parties to the License Agreement
Licensor: Penterra Pharmaceuticals Corp. ("PPC")
PPC is a corporation organized under the laws of the State of Delaware, with its principal headquarters located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." For its fiscal year ending December 31, 2020, PPC reported consolidated revenue of approximately $6.82 billion. PPC is the ultimate parent entity of the Penterra group and is the U.S. taxpayer whose federal income tax returns for tax years 2017 through 2020 are under examination. PPC is the owner of all intellectual property associated with the legacy compound portfolio at issue in this analysis and serves as the licensor under the License Agreement.
Licensee: Penterra Biopharma International DAC ("PBI")
PBI is a Designated Activity Company organized under the laws of Ireland, with its registered office located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI is wholly owned by PPC through an intermediate holding company, Penterra Holdings Luxembourg S.à r.l. ("PHL"), which is organized under the laws of the Grand Duchy of Luxembourg with its registered office at 14, rue Aldringen, L-1118 Luxembourg. PHL is treated as a disregarded entity for U.S. federal income tax purposes under the check-the-box regulations of Treas. Reg. § 301.7701-3, such that PBI is treated for U.S. tax purposes as a controlled foreign corporation ("CFC") directly owned by PPC.
PBI functions as the intellectual property-holding company and operational principal for the non-Americas commercialization of the Penterra group's pharmaceutical products. In this capacity, PBI manages contract manufacturing operations through Penterra Manufacturing Ireland Ltd. ("PMI"), a related Irish entity that manufactures products at its facility in Ringaskiddy, County Cork, Ireland, under a contract manufacturing agreement at a cost-plus markup of 8%. PBI also enters into and manages distribution arrangements and local marketing operations across the EMEA and APAC territories through a network of affiliated and third-party distributors.
PBI's Managing Director is Aidan Naughton, who exercises genuine decision-making authority over PBI's non-Americas commercial operations from Dublin. PBI's employee headcount has grown substantially since its incorporation, from 52 employees in 2012 to 185 employees by the end of 2020, reflecting the expansion of its commercial operations and the increasing scope of its responsibilities across its licensed territories.
B. The License Agreement — Key Terms
The License Agreement was executed contemporaneously with, or shortly after, PBI's incorporation on March 15, 2012, and the CSA that became effective on July 1, 2012. The License Agreement covers pharmaceutical compounds that were not included within the scope of the CSA — that is, pre-2012 vintage compounds that PPC developed prior to the formation of the cost-sharing arrangement and that were explicitly excluded from the CSA and the PCT. The material terms of the License Agreement are summarized below.
Scope of License. Under the License Agreement, PBI receives an exclusive license to exploit certain legacy pharmaceutical compounds in the non-Americas territory. The non-Americas territory is defined as all territories worldwide excluding North America (the United States and Canada), Central America, South America, and the Caribbean. The legacy compounds are primarily mature oncology and specialty pharmaceutical products that PPC developed and commercialized prior to 2012 and for which PPC retains full ownership of all underlying intellectual property, including patents, know-how, regulatory dossiers, trademarks, and trade secrets.
Royalty Rate. The License Agreement provides for a running royalty of 4.5% of net sales generated by PBI from the sale of legacy compounds in the licensed territory. This royalty rate was established at the time of PBI's formation based on a benchmarking study conducted by Crestfield & Associates LLP and has remained constant since inception.
Royalty Base. The royalty is calculated on net sales, defined as gross sales less returns, rebates, discounts, and allowances. This definition is standard in the pharmaceutical industry and consistent with the royalty base definitions observed in the comparable uncontrolled transactions used in the benchmarking analysis.
Payment Terms. Royalty payments are made quarterly in arrears, within thirty (30) days following the end of each calendar quarter, based on PBI's net sales of legacy compounds in the licensed territory during the preceding quarter.
Duration. The License Agreement is coterminous with the remaining patent and regulatory exclusivity periods for each individual legacy compound. As each compound loses patent protection or regulatory exclusivity in a given market within the licensed territory, the royalty obligation with respect to that compound in that market terminates. The License Agreement also contains provisions for renegotiation of terms upon patent expiry for individual compounds, reflecting the parties' understanding that the value of the licensed IP diminishes over time as exclusivity periods expire and generic competition enters the market.
Sub-licensing. PBI has the right to sub-license the legacy compounds or appoint distributors within the licensed territory, subject to certain quality and reporting requirements. PBI bears the full commercial risk associated with the exploitation of the legacy compounds in the non-Americas territory, including demand risk, pricing risk, regulatory risk, and credit risk associated with its customers and sub-licensees.
Improvements and Enhancements. Any improvements or enhancements to the legacy compounds developed after July 1, 2012, that fall outside the scope of the CSA are addressed through amendment protocols set forth in the License Agreement. These protocols provide for the negotiation of supplemental royalty terms or lump-sum payments to reflect the value of such improvements, determined on an arm's-length basis.
C. Legacy Compound Portfolio — Financial Overview
The legacy compounds subject to the License Agreement are mature pharmaceutical products with declining revenue trajectories. This declining trend reflects the natural product lifecycle of these compounds, including loss of patent exclusivity in key markets, increasing generic competition, formulary pressures from healthcare payors, and the natural attrition of market share as newer therapeutic alternatives are introduced. The declining revenue trend is a function of product maturity and lifecycle erosion, not a pricing deficiency in the royalty rate established under the License Agreement.
The following table summarizes non-Americas net sales for the legacy compound portfolio and corresponding royalty payments to PPC during the examination years:
As reflected in the table above, non-Americas net sales of legacy compounds declined by approximately 23.4% from $814.6 million in 2017 to $624.1 million in 2020, and corresponding royalty payments to PPC declined from $36.66 million to $28.08 million over the same period. This declining trajectory is fully consistent with the lifecycle profile of the legacy compound portfolio and provides important context for the arm's-length analysis: a fixed royalty rate applied to a declining revenue base produces naturally decreasing compensation to the licensor, which is the expected economic outcome for licensing mature, declining-value IP assets.
D. Distinction from CSA-Covered IP
It is critical to distinguish the legacy compounds covered by the License Agreement from the intellectual property covered by the CSA between PPC and PBI. The CSA, effective July 1, 2012, governs the development and exploitation of IP that is developed or enhanced through the joint research and development cost-sharing arrangement between PPC and PBI. At the inception of the CSA, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC to acquire buy-in rights to the pre-existing IP that was contributed to the CSA as the platform for future joint development.
The legacy compounds at issue in this memorandum are explicitly excluded from the CSA and the PCT. These compounds were not contributed to the CSA, were not the subject of the PCT payment, and remain 100% owned by PPC. They are licensed to PBI under the separate License Agreement analyzed herein, and the royalty payments made by PBI under the License Agreement are the sole compensation to PPC for the use of this legacy IP in the non-Americas territory.
For context and contrast, the following are key CSA-covered products that are not subject to the legacy IP royalty:
•  Veritaxol (oncology): Global net sales of $3.12 billion in 2020; non-Americas net sales of $1.34 billion.
•  Imvara (immunology): Global net sales of $1.87 billion in 2020; non-Americas net sales of $790 million.
•  Cerulon (rare disease): Global net sales of $620 million in 2020; non-Americas net sales of $280 million.
These growth-stage and blockbuster products are governed by the CSA's cost-sharing mechanism and are addressed in separate analyses. The legacy compounds, by contrast, are mature products with declining revenues and diminishing patent protection — a fundamentally different economic profile that bears directly on the appropriate royalty rate.
E. Relationship to the IRS Examination
On May 16, 2022, the IRS issued Letter 2205-A initiating an examination of PPC's federal income tax returns for tax years 2017 through 2020. The examination is being conducted by Exam Team LB&I-NE-TP-2022-00641, with Lead Revenue Agent Patricia Dunleavy and Supervisory Revenue Agent/Team Manager Gerald Meskill.
Based on the examination scope and the initial IDR requests issued by the examination team (the first batch of IDRs was received in June 2022), it is clear that the IRS intends to scrutinize PPC's transfer pricing arrangements with PBI, including both the legacy IP royalty rate under the License Agreement and the CSA cost-sharing ratios. The examination team has specifically requested copies of the intercompany agreements between PPC and PBI, including the License Agreement, as well as the contemporaneous transfer pricing documentation, financial statements, and supporting workpapers.
Based on publicly available IRS guidance, recent examination outcomes in the pharmaceutical industry, and the general enforcement posture of the IRS Large Business & International ("LB&I") division's transfer pricing practice, we anticipate that the IRS will challenge the 4.5% legacy IP royalty rate as being below the arm's-length standard. The IRS's anticipated position is that the royalty rate should be increased, potentially to 11.0% or more, based on the IRS's own selection of CUT comparables drawn from pharmaceutical licensing agreements involving higher-value, growth-stage, or blockbuster IP. We address the anticipated IRS challenge and our recommended rebuttal arguments in detail in Section VII below.
PPC's contemporaneous transfer pricing documentation, prepared by Susan Lam, Transfer Pricing Partner at Crestfield & Associates LLP, establishes the 4.5% royalty rate as arm's-length using the CUT method as the best method. The documentation was prepared for each of tax years 2017 through 2020 and is available to support PPC's position in the examination.
III. Applicable Legal and Regulatory Framework
A. IRC § 482 — General Principles
Section 482 of the Internal Revenue Code authorizes the Secretary of the Treasury to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any such organizations, trades, or businesses.
The operative standard under Section 482 is the arm's-length standard. Under this standard, controlled transactions — that is, transactions between related parties — must reflect terms and conditions that would have been agreed upon between unrelated parties dealing at arm's length under comparable circumstances. The arm's-length standard is the cornerstone of U.S. transfer pricing law and reflects the principle that related-party transactions should be priced as if the parties were independent market participants, thereby preventing the artificial shifting of income among commonly controlled entities.
As set forth in Treas. Reg. § 1.482-1(b)(1), the purpose of Section 482 is to place a controlled taxpayer on tax parity with an uncontrolled taxpayer by determining the true taxable income of the controlled taxpayer. The regulations further provide that, in determining the true taxable income of a controlled taxpayer, the standard to be applied is that of a taxpayer dealing at arm's length with an uncontrolled taxpayer. The controlled taxpayer's dealings with the commonly controlled entity must yield results consistent with those that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.
Importantly, the burden of proof in a Section 482 case generally rests with the IRS to establish that the taxpayer's transfer pricing does not reflect an arm's-length result, although this burden can shift in certain circumstances. The taxpayer, in turn, must demonstrate that it applied a reasonable transfer pricing methodology and maintained adequate documentation to support its pricing.
B. Treas. Reg. § 1.482-4 — Methods for Determining Arm's-Length Consideration for Intangible Property
The regulations under Section 482 provide specific guidance for determining the arm's-length consideration for transfers of intangible property between controlled parties. Treas. Reg. § 1.482-4 sets forth the applicable methods and standards for intangible property transactions, including licensing arrangements such as the License Agreement at issue here.
Section 1.482-4(a): Commensurate-with-Income Standard. Treas. Reg. § 1.482-4(a) provides that the arm's-length consideration for the transfer of intangible property must be "commensurate with the income attributable to the intangible." This standard, enacted as part of the Tax Reform Act of 1986, imposes a heightened requirement that the royalty rate for intangible property transfers reflect the actual income generated by the intangible, rather than being fixed at a rate that may have been reasonable at inception but no longer reflects the true value of the IP. As discussed further below in connection with the periodic adjustment rule, this standard is particularly relevant to the legacy compound portfolio, where declining revenues suggest that the 4.5% rate, if anything, may be generous to the licensor (PPC) rather than understated.
Section 1.482-4(b): Specified Methods. The regulations identify four categories of methods for determining the arm's-length consideration for intangible property transfers:
1.  The Comparable Uncontrolled Transaction ("CUT") method, set forth in § 1.482-4(c);
2.  The Comparable Profits Method ("CPM"), set forth in § 1.482-5;
3.  The Profit Split Method, set forth in § 1.482-6; and
4.  Unspecified methods, as permitted under § 1.482-4(d).
Section 1.482-4(c): The CUT Method. The CUT method determines an arm's-length royalty rate by reference to the amount charged in a comparable uncontrolled transaction — that is, a transaction between unrelated parties involving the transfer of comparable intangible property under comparable circumstances. The CUT method is the most direct and reliable method for testing a royalty rate when sufficiently comparable uncontrolled license agreements can be identified.
The comparability factors relevant to the CUT method include the similarity of the intangible property (type, terms, stage of development, exclusivity, geographic scope, profit potential) and the similarity of the circumstances surrounding the transaction (contractual terms, economic conditions, property or services involved, geographic market, and risks borne by each party). The reliability of the CUT method is enhanced when exact comparables or close comparables can be identified; where material differences exist between the controlled and uncontrolled transactions, adjustments may be made under Treas. Reg. § 1.482-1(d)(2) to improve comparability.
Section 1.482-4(d): Periodic Adjustment Rule. The periodic adjustment rule permits the IRS to adjust royalty rates in subsequent years if the actual results of the controlled transaction diverge significantly from the projections used to set the royalty rate at inception. This rule gives effect to the "commensurate with income" standard by ensuring that royalty rates continue to reflect the economic reality of the intangible property's income-generating capacity over time. As discussed below, the periodic adjustment rule is relevant to the legacy compound portfolio, but it cuts in PPC's favor: because legacy compound revenues are declining, a periodic adjustment analysis would, if anything, support a lower royalty rate or confirm the existing rate rather than requiring an upward adjustment.
Section 1.482-4(f)(2): Definition of Intangible Property. The regulations define intangible property broadly to include patents, inventions, formulae, processes, designs, patterns, know-how, copyrights, literary, musical, or artistic compositions, trademarks, trade names, brand names, franchises, licenses, contracts, methods, programs, systems, procedures, campaigns, surveys, studies, forecasts, estimates, customer lists, and technical data. All of these categories are potentially applicable to the legacy compound portfolio, which encompasses patents, pharmaceutical know-how, manufacturing processes, regulatory dossiers, trademarks, and trade secrets associated with the marketed pharmaceutical products.
C. Treas. Reg. § 1.482-1(c) — Best Method Rule
The best method rule, set forth in Treas. Reg. § 1.482-1(c), requires that the arm's-length result of a controlled transaction be determined under the method that provides the most reliable measure of an arm's-length result. No single method is presumptively the best; rather, the selection of the best method depends on the facts and circumstances of each case.
The two primary factors in determining the best method are: (1) the degree of comparability between the controlled transaction and any uncontrolled transactions, and (2) the quality of the data and assumptions used in the analysis. The method that achieves the highest degree of comparability between the controlled and uncontrolled transactions and that relies on the highest quality data and assumptions is the most reliable and therefore constitutes the best method.
As discussed in Section IV below, we have determined that the CUT method is the best method for analyzing the legacy IP royalty under the License Agreement. This conclusion is based on the availability of a substantial set of comparable uncontrolled pharmaceutical license agreements, the directness of the CUT method in testing the royalty rate at issue, and the superior reliability of the CUT analysis relative to alternative methods.
D. Treas. Reg. § 1.482-1(d) — Comparability Standards
The comparability analysis required under the regulations considers five principal factors: (1) the functions performed by each party to the transaction, (2) the contractual terms of the transaction, (3) the risks assumed by each party, (4) the economic conditions and market circumstances, and (5) the property or services transferred. Each of these factors must be evaluated in determining whether an uncontrolled transaction is sufficiently comparable to the controlled transaction to serve as a reliable benchmark.
When multiple comparable transactions are identified, an arm's-length range is established based on the results of those transactions. Under Treas. Reg. § 1.482-1(e)(2), the arm's-length range is typically defined by the interquartile range — that is, the range between the 25th percentile and the 75th percentile of the results of the comparable transactions. If the tested party's results fall within the interquartile range, no adjustment is warranted. If the tested party's results fall outside the interquartile range, the IRS may adjust the results to the median of the comparable transactions.
This framework is directly applicable to the legacy IP royalty analysis. As demonstrated below, PPC's 4.5% royalty rate falls within the IQR of 3.1% to 6.8% established by the set of 14 comparable uncontrolled transactions, and no adjustment is warranted.
E. Treas. Reg. § 1.482-1(f)(2)(iii) — Contemporaneous Documentation
The transfer pricing regulations provide that contemporaneous documentation may serve as evidence that the taxpayer made a reasonable effort to comply with the arm's-length standard. The existence of contemporaneous documentation is relevant to the penalty protection analysis under IRC § 6662(e), as it supports a reasonable-cause defense against the imposition of the substantial valuation misstatement penalty. PPC maintained contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP for each of the four examination years, documenting the 4.5% legacy IP royalty rate under the CUT method. A detailed analysis of penalty protection is addressed in a separate memorandum.
F. IRC § 6662(e) — Substantial Valuation Misstatement (Transfer Pricing)
Section 6662(e) of the Internal Revenue Code imposes a 20% accuracy-related penalty in the case of a substantial valuation misstatement in connection with a Section 482 transfer pricing adjustment. A substantial valuation misstatement exists if the transfer price claimed by the taxpayer is 200% or more (or 50% or less) of the correct price, and the net Section 482 transfer pricing adjustment for the taxable year exceeds $5 million (or a lesser threshold in certain cases). The penalty increases to 40% in the case of a gross valuation misstatement (400% or more, or 25% or less, of the correct price, with a net adjustment exceeding $20 million).
The potential applicability of this penalty is a significant consideration in the legacy IP royalty analysis. If the IRS were to propose that the correct royalty rate is 11.0% (as anticipated), the 4.5% rate claimed by PPC would represent approximately 40.9% of the IRS-proposed rate — potentially triggering the substantial valuation misstatement threshold (50% or less of the correct price). However, the penalty is subject to a reasonable-cause exception, and PPC's contemporaneous documentation and reasonable methodology provide a strong basis for a reasonable-cause defense. A separate penalty analysis memorandum is forthcoming from Garrett Simmons, targeted for completion by September 2, 2022.
G. OECD Transfer Pricing Guidelines — Persuasive Authority
The Organisation for Economic Co-operation and Development ("OECD") Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (the "OECD Guidelines"), including the 2017 and 2022 revisions, are frequently cited as persuasive authority in U.S. transfer pricing cases. While not binding on U.S. courts, the OECD Guidelines are recognized as reflecting international consensus on transfer pricing principles and are often referenced by both taxpayers and the IRS in developing and evaluating transfer pricing analyses.
Chapter VI of the OECD Guidelines addresses the transfer pricing of intangibles and provides guidance on the identification, characterization, and valuation of intangible property in controlled transactions. Chapter II addresses the selection and application of transfer pricing methods, including the comparable uncontrolled price ("CUP") method, which is the OECD analogue to the U.S. CUT method.
The OECD CUP methodology is substantially analogous to the U.S. CUT method and supports the comparability analysis approach undertaken in this memorandum. The OECD's guidance on the selection of the "most appropriate method" is also broadly consistent with the best method rule under U.S. regulations, and the OECD's emphasis on functional analysis, comparability factors, and the arm's-length principle reinforces the analytical framework applied herein.
IV. Best Method Analysis — Selection of CUT Method for Legacy IP Royalty
A. Why CUT Is the Best Method
The CUT method is the best method for evaluating the arm's-length character of the 4.5% royalty rate under the License Agreement. This conclusion is based on the following considerations.
First, the legacy IP license involves a straightforward royalty-for-license structure — PPC, as the licensor, grants PBI an exclusive license to exploit specified pharmaceutical IP in a defined territory in exchange for a running royalty calculated as a percentage of net sales. This type of licensing arrangement is ubiquitous in the pharmaceutical industry, and publicly available and proprietary licensing databases contain a substantial body of comparable uncontrolled transactions involving similar structures. The pharmaceutical industry, more than perhaps any other sector, generates a rich data set of arm's-length license agreements that can be used as benchmarks for CUT analysis, because pharmaceutical companies frequently enter into licensing agreements with unrelated parties for the development, manufacture, and commercialization of pharmaceutical products.
Second, the CUT method provides the most direct and reliable measure of an arm's-length royalty rate when sufficiently comparable license agreements can be identified. Unlike alternative methods that test profitability or allocate combined profits, the CUT method directly tests the price (royalty rate) charged in the controlled transaction by reference to the price charged in comparable uncontrolled transactions. This directness makes the CUT method inherently more reliable for testing a specific royalty rate, provided that the comparability requirements are met.
Third, the CUT analysis performed by Whitmore Valuation Group LLC (discussed in Section V below) identified 14 comparable uncontrolled transactions that meet the comparability standards of the regulations. The availability of this substantial set of comparables provides a robust empirical basis for the CUT analysis and enhances its reliability relative to alternative methods.
Fourth, the selection of the CUT method is consistent with the methodological approach taken by Crestfield & Associates LLP in the contemporaneous transfer pricing documentation prepared for each of the four examination years. Consistency between the contemporaneous documentation and the current defense analysis strengthens PPC's overall position and mitigates the risk that the IRS will characterize PPC's methodology as opportunistic or post hoc.
B. Limitations of Alternative Methods
We considered and rejected the following alternative methods as less reliable than the CUT method for the legacy IP royalty analysis.
Comparable Profits Method ("CPM") / Transactional Net Margin Method ("TNMM"). The CPM (or its OECD equivalent, the TNMM) tests the arm's-length character of a controlled transaction by comparing the net profitability of the tested party (either the licensee or the licensor) with the net profitability of comparable uncontrolled companies performing similar functions and bearing similar risks. While the CPM is a useful and widely accepted method for many types of intercompany transactions, it is less reliable than the CUT method for testing a specific royalty rate. The CPM tests profitability, not the royalty rate itself, and therefore introduces additional layers of analysis and assumption that reduce reliability when direct CUT comparables are available. The CPM may be more appropriate for the CSA cost-sharing analysis (which is addressed in a separate memorandum) but is not the best method for the legacy IP royalty at issue here.
Profit Split Method. The profit split method allocates the combined profits of the controlled parties between or among them based on their relative contributions to the combined profit. While the profit split method can be appropriate for transactions involving unique and valuable intangible property where both parties make significant contributions, it is inherently more complex and introduces substantial subjectivity in the determination of profit allocation keys. When direct CUT comparables are available — as they are here — the profit split method is less reliable because it does not directly test the royalty rate and requires additional assumptions about the appropriate division of profits. The profit split method may, however, be relevant as a cross-check on the CUT analysis, and we recommend that Whitmore Valuation Group consider performing a confirmatory profit split analysis to buttress the CUT results.
Unspecified Methods. Treas. Reg. § 1.482-4(d) permits the use of unspecified methods — that is, methods not specifically identified in the regulations — where no specified method provides a reliable result. Given the availability of 14 CUT comparables providing a robust arm's-length range, there is no need to resort to unspecified methods. The use of an unspecified method in these circumstances would not only be unnecessary but could also undermine PPC's position by suggesting that the specified methods are inadequate.
C. Consistency with Crestfield Documentation
Susan Lam at Crestfield & Associates LLP selected the CUT method as the best method for the legacy IP royalty analysis in the contemporaneous transfer pricing documentation prepared for all four tax years (2017–2020). This selection was based on the same factors discussed above — the availability of comparable uncontrolled pharmaceutical license agreements, the directness and reliability of the CUT method for testing a royalty rate, and the superior quality of the CUT data relative to the data available for alternative methods. Our independent analysis confirms and supports the best method determination made in the contemporaneous documentation.
V. Comparability Analysis — Application of CUT Method
A. Identification of Comparable Uncontrolled Transactions
To support PPC's defense of the 4.5% royalty rate, Calderwood & Harkness has engaged Whitmore Valuation Group LLC to perform an independent economic analysis, including a CUT benchmarking study for the legacy IP royalty. Whitmore Valuation Group has been retained under a Kovel arrangement to ensure that its work product is protected by the attorney-client privilege and work product doctrine. The Kovel engagement letter is referenced as 1018-00009-KV and was executed on June 20, 2022.
The Whitmore engagement team is led by Dr. Helena Vasquez, Managing Director, and Dr. Rohan Chakrabarti, Senior Director. Both Dr. Vasquez and Dr. Chakrabarti have extensive experience in pharmaceutical transfer pricing and intangible valuation and have served as testifying experts in numerous transfer pricing disputes.
Whitmore identified 14 comparable uncontrolled pharmaceutical license agreements through a comprehensive search of public filings (including SEC filings, patent databases, and publicly available licensing disclosures) and proprietary licensing databases. The search was designed to identify license agreements between unrelated parties that are sufficiently comparable to the License Agreement between PPC and PBI to serve as reliable benchmarks under the CUT method.
The search criteria and screening process applied by Whitmore included the following parameters:
•  Industry: Pharmaceutical and biotechnology industry.
•  Transaction Type: Intangible property licenses involving patents, know-how, regulatory dossiers, and/or related IP rights for marketed or late-stage pharmaceutical compounds.
•  Territorial Scope: Non-Americas or global territorial scope (licenses limited to the U.S. market only were excluded as not comparable to PBI's non-Americas territory).
•  Exclusivity: Exclusive or semi-exclusive licenses (non-exclusive licenses were excluded as not comparable to PBI's exclusive license).
•  Execution Date: Agreements executed after 2005, to ensure relevance to current market conditions and industry practices.
•  Licensee Risk Profile: Licensee bearing commercialization risk, including market risk, pricing risk, regulatory risk, and distribution risk (agreements where the licensor retained significant commercialization risk were excluded as not comparable).
•  Product Stage: Marketed products or late-stage compounds with approved regulatory filings (early-stage or preclinical compounds were excluded as not comparable to PPC's marketed legacy products).
After applying these screening criteria, Whitmore identified an initial set of approximately 38 potential comparable agreements. This set was further refined through detailed review of the agreement terms, financial characteristics, and comparability factors, resulting in the final set of 14 comparable uncontrolled transactions used in the benchmarking analysis. The details of these 14 agreements are summarized in Appendix A to this memorandum.
B. Comparability Factors Applied
The 14 CUT comparables were evaluated against the controlled transaction (the License Agreement) using the five principal comparability factors set forth in Treas. Reg. § 1.482-1(d). The analysis of each factor is summarized below.
1. Nature of Intangible Property. All 14 CUT comparables involve pharmaceutical intellectual property, including patents, know-how, regulatory dossiers, and related IP rights for marketed or late-stage pharmaceutical compounds. The intangible property in the CUT comparables is of a similar type to the legacy compounds licensed under the License Agreement — namely, pharmaceutical IP covering marketed products with established regulatory approvals and commercial track records. Particular attention was paid to selecting comparables involving products at a similar lifecycle stage to the legacy compounds (i.e., mature products with established market positions and, in many cases, facing declining revenue trajectories due to patent expiration, generic competition, or therapeutic obsolescence). Several of the 14 CUT comparables specifically involve mature pharmaceutical products with declining revenue profiles, enhancing comparability with PPC's legacy compound portfolio.
2. Contractual Terms. The CUT comparables involve exclusive territorial licenses with royalty-based compensation structures — consistent with the License Agreement between PPC and PBI. Adjustments were considered for differences in sub-licensing rights, milestone payment provisions, minimum royalty requirements, and other contractual features that could affect the effective royalty rate. Where material differences were identified, appropriate comparability adjustments were applied, as discussed in Section V.D below.
3. Geographic Scope. The selected CUT comparables involve licenses for international territories, including ex-U.S., ex-Americas, and global (excluding the licensor's home market) territorial grants. This geographic scope is comparable to PBI's non-Americas territory under the License Agreement. CUT comparables limited to the U.S. market were excluded from the analysis, as the U.S. pharmaceutical market has distinct pricing dynamics, regulatory characteristics, and competitive conditions that may not be representative of the EMEA and APAC markets in which PBI operates.
4. Functions Performed / Risks Assumed. In each of the 14 CUT comparables, the licensee performs substantial commercialization functions, including marketing, distribution, pricing, regulatory maintenance, and medical affairs. The licensees in the CUT comparables also assume commercial risk associated with the exploitation of the licensed products, including demand risk, pricing risk, regulatory risk, and credit risk. This functional and risk profile is consistent with PBI's role under the License Agreement. PBI is a substantive operating entity that employs 185 people, maintains approximately 18,000 square feet of office space at Sandyford Business Park in Dublin, conducts independent pricing and commercial strategy across 68 country markets in the EMEA and APAC regions, and manages regulatory submissions and maintenance at a cumulative cost of €47.2 million over the 2017–2020 period. PBI's substantive functions and risk-bearing further support the comparability of PBI's position as licensee with the licensees in the CUT comparables.
5. Economic Conditions. The CUT comparables were executed between 2005 and 2020, a period that encompasses a range of economic conditions and pharmaceutical industry dynamics broadly comparable to those prevailing during the term of the License Agreement. Where differences in economic conditions were identified that could materially affect comparability (e.g., differences in market maturity, competitive intensity, or regulatory environment), such differences were considered in the comparability analysis and, where appropriate, reflected in comparability adjustments.
6. Product Maturity. As noted above, the legacy compounds licensed under the License Agreement are mature products with declining revenue trajectories. This product maturity characteristic is a critical comparability factor, because the expected future income attributable to a mature, declining product is lower than the expected future income attributable to a growth-stage or blockbuster product, and this difference should be reflected in the royalty rate. Several of the 14 CUT comparables involve mature pharmaceutical products with comparable lifecycle characteristics, supporting the relevance and reliability of the arm's-length range derived from the CUT analysis.
C. Arm's-Length Range and Median
Based on the analysis of the 14 comparable uncontrolled transactions, Whitmore Valuation Group established the following arm's-length range for the legacy IP royalty rate:
PPC's royalty rate of 4.5% of net sales falls squarely within the interquartile range of 3.1% to 6.8% and is proximate to the median of 4.4%, positioned just 0.1 percentage point above the median. Under Treas. Reg. § 1.482-1(e)(2), no adjustment to the tested price is warranted when the tested price falls within the arm's-length range established by comparable uncontrolled transactions. Accordingly, PPC's 4.5% royalty rate is arm's-length under the CUT method.
The proximity of PPC's royalty rate to the median is particularly significant because, in the event the IRS were to determine that the 4.5% rate falls outside the arm's-length range (which we do not expect, given the robustness of the CUT analysis), the median is the point to which the IRS would adjust under the regulations. The fact that PPC's rate is virtually identical to the median provides an additional layer of protection and further demonstrates the arm's-length character of the royalty.
D. Comparability Adjustments
In the course of the CUT analysis, Whitmore Valuation Group considered whether comparability adjustments were warranted to account for material differences between the controlled transaction and the comparable uncontrolled transactions. The following adjustments and considerations were addressed:
•  Territory size adjustments: Where CUT comparables involved territories that were materially larger or smaller than PBI's non-Americas territory, adjustments were considered to normalize the royalty rates for differences in market size, revenue potential, and commercial complexity. In most cases, the territorial scope of the CUT comparables was sufficiently similar to PBI's territory that no material adjustment was required.
•  Product stage adjustments: As noted above, the CUT analysis focused on comparables involving mature pharmaceutical products with characteristics similar to the legacy compound portfolio. Where individual CUT comparables involved products at a slightly different lifecycle stage (e.g., late-stage products with some remaining growth potential), adjustments were considered to reflect the impact of product maturity on the royalty rate.
•  Exclusivity adjustments: The License Agreement grants PBI an exclusive license. Most of the CUT comparables also involve exclusive licenses, minimizing the need for exclusivity adjustments. Where semi-exclusive or co-exclusive arrangements were included in the CUT set, the royalty rates were adjusted to reflect the higher value typically associated with exclusivity.
•  Volume commitment and minimum royalty adjustments: Certain CUT comparables included minimum royalty provisions or volume commitments that are not present in the License Agreement. These provisions can affect the effective royalty rate by providing the licensor with a floor on compensation; adjustments were made to normalize for these differences where appropriate.
It is important to note that none of the comparability adjustments applied in the analysis would move PPC's 4.5% royalty rate outside the interquartile range. The adjustments are modest and reflect standard practice in CUT analyses, and their application enhances rather than diminishes the reliability of the arm's-length range.
We also acknowledge certain limitations and data quality issues inherent in publicly available licensing databases. Public filings do not always disclose the complete terms of license agreements, and certain financial details (such as milestone payment structures or the net sales attributable to specific licensed products) may not be publicly available. These limitations are common to all CUT analyses in the pharmaceutical industry and do not undermine the reliability of the analysis, which is based on the best available data and supplemented by information from proprietary licensing databases where possible.
VI. Analysis of Key Terms of the Legacy IP License Agreement
A. Royalty Rate (4.5%)
The 4.5% royalty rate was established at the time of PBI's formation in 2012 based on a benchmarking study conducted by Crestfield & Associates LLP. The study identified comparable uncontrolled pharmaceutical license agreements and determined that a 4.5% royalty rate was within the arm's-length range for the licensing of mature pharmaceutical compounds in the non-Americas territory. The rate has remained constant since inception, which is consistent with the fixed-rate royalty provisions commonly observed in the CUT comparables and in pharmaceutical licensing practice generally.
The stability of the royalty rate over time is a feature, not a deficiency, of the License Agreement. Fixed-rate royalty provisions are commonplace in arm's-length pharmaceutical license agreements, particularly for mature products where the parties have sufficient information to establish a rate at inception that reflects the expected value of the license over its remaining term. The use of a fixed rate provides certainty and simplicity for both parties and avoids the administrative burden and potential disputes associated with periodic rate renegotiation.
Under the periodic adjustment rule of Treas. Reg. § 1.482-4(d), the IRS has the authority to adjust royalty rates in subsequent years if the actual income attributable to the intangible property diverges significantly from the projections used to set the rate at inception. This rule is intended to ensure that the royalty rate remains "commensurate with income" over time, as required by § 1.482-4(a). However, the periodic adjustment rule cuts strongly in PPC's favor in this case. The legacy compound portfolio has experienced a consistent and significant decline in non-Americas net sales over the examination period, from $814.6 million in 2017 to $624.1 million in 2020 — a decline of approximately 23.4%. This declining revenue trajectory is fully consistent with the product lifecycle characteristics of the legacy compounds (patent expiration, generic competition, therapeutic obsolescence) and indicates that the actual income attributable to the licensed IP is declining, not increasing.
If anything, a periodic adjustment analysis applied to the legacy IP royalty would support a lower royalty rate, not a higher one, because the declining revenue base means that PPC's absolute compensation is already decreasing over time. A fixed 4.5% rate on a shrinking royalty base does not suggest undercompensation to PPC; to the contrary, it suggests that PPC is receiving a stable percentage of a declining income stream, which is the expected economic outcome for a licensor of mature, declining-value IP.
B. Royalty Base (Net Sales)
The royalty under the License Agreement is calculated on net sales, defined as gross sales less returns, rebates, discounts, and allowances. This definition is standard and widely used in the pharmaceutical industry, both in controlled and uncontrolled transactions. The net sales definition ensures that the royalty base reflects the actual economic value of the product sales, after accounting for the customary deductions and adjustments that reduce gross revenue to net revenue in the pharmaceutical industry (including government-mandated rebates, managed care discounts, wholesaler chargebacks, and patient assistance program adjustments).
The net sales figures used to calculate royalty payments are derived from PBI's financial records, which are maintained in accordance with International Financial Reporting Standards ("IFRS") and audited by PBI's Irish statutory auditors. PBI's treasury operations are conducted through Glenmore Bank Ireland plc. The net sales data is auditable and readily verifiable, providing a transparent and reliable basis for royalty calculation.
The use of net sales as the royalty base is also consistent with the royalty base definitions observed in the 14 CUT comparables, further supporting the comparability of the License Agreement with arm's-length pharmaceutical licensing transactions.
C. Territorial Scope
The License Agreement grants PBI an exclusive license to exploit the legacy compounds in the non-Americas territory, defined to include the EMEA and APAC regions. This territorial delineation is consistent with PBI's overall commercial mandate as the Penterra group's principal for non-Americas operations and mirrors the territorial delineation used in the CSA between PPC and PBI. The non-Americas territory encompasses approximately 68 country markets in which PBI conducts commercial operations, ranging from major developed markets (e.g., Germany, France, United Kingdom, Japan, Australia) to emerging markets (e.g., China, Brazil, India, Turkey, South Korea).
The exclusivity of the license is an important comparability factor in the CUT analysis. An exclusive license typically commands a different royalty rate than a non-exclusive license, because the exclusive licensee bears greater commercial risk and has a stronger incentive to invest in commercialization activities. The exclusivity of PBI's license is consistent with the exclusive licenses observed in the CUT comparables, and the royalty rate reflects this exclusivity.
D. Sub-licensing and Distribution
Under the License Agreement, PBI has the right to sub-license the legacy compounds or appoint distributors within the licensed territory, subject to certain quality control and reporting obligations. PBI exercises this right by entering into distribution agreements with affiliated and third-party distributors in the various country markets within the non-Americas territory. PBI bears the full commercial risk associated with the sub-licensing and distribution of the legacy compounds, including the risk that distributors may fail to achieve targeted sales volumes, that sub-licensees may breach their obligations, or that market conditions may adversely affect sales performance.
This allocation of sub-licensing rights and commercial risk to PBI is consistent with the CUT comparables, in which the licensee typically has the right to appoint distributors and sub-licensees and bears the associated commercial risk. The fact that PBI bears these risks supports its characterization as the risk-bearing licensee and supports the appropriateness of a royalty rate that compensates PPC (the licensor) for the use of its IP while allowing PBI to retain the residual returns from its commercialization activities.
E. Duration and Termination
The License Agreement is coterminous with the remaining patent and regulatory exclusivity periods for each individual legacy compound in each country within the licensed territory. As each compound loses patent protection or regulatory exclusivity in a given market, the royalty obligation with respect to that compound in that market terminates. This structure means that the License Agreement's effective scope and the royalty base naturally decline over time as the legacy compound portfolio loses exclusivity — a feature that is fully consistent with the declining revenue trajectory observed during the examination years.
The declining-revenue, declining-base structure of the License Agreement is an important factor supporting the reasonableness of the 4.5% royalty rate. Because PPC's compensation under the License Agreement is a fixed percentage of a declining royalty base, PPC's absolute compensation decreases naturally as the value of the licensed IP diminishes. This self-adjusting mechanism ensures that PPC's compensation remains commensurate with the income attributable to the intangible property, as required by the regulations, without the need for periodic renegotiation of the royalty rate.
The License Agreement also contains provisions for renegotiation of terms upon patent expiry for individual compounds, providing the parties with flexibility to adjust the arrangement as the legacy compound portfolio evolves.
F. Payment Mechanics
Royalty payments under the License Agreement are made quarterly in arrears, within thirty (30) days following the end of each calendar quarter. This payment schedule is standard in pharmaceutical licensing practice and is consistent with the payment terms observed in the CUT comparables. Quarterly payment in arrears ensures timely cash flow to the licensor while aligning the payment schedule with the licensee's financial reporting cycle.
VII. Anticipated IRS Challenge and Rebuttal
A. Expected IRS Position
Based on examination trends in the pharmaceutical industry, the known focus areas of the LB&I division's transfer pricing practice, and the scope and nature of the initial IDR requests issued by Exam Team LB&I-NE-TP-2022-00641, we anticipate that the IRS will challenge the 4.5% legacy IP royalty rate on the following grounds:
1.  The royalty rate is below the arm's-length range. The IRS is likely to argue that 4.5% is below the arm's-length range for pharmaceutical IP licenses and that the rate should be substantially higher — potentially 11.0% or more. This argument would be based on the IRS's own selection of CUT comparables, which we anticipate will include pharmaceutical licensing agreements involving growth-stage or blockbuster compounds that command higher royalty rates.
2.  Higher-rate CUT comparables. The IRS may cite pharmaceutical licensing agreements involving high-value, growth-stage, or blockbuster pharmaceutical compounds and argue that these agreements are comparable to PPC's legacy compound portfolio. If the IRS selects CUT comparables at higher rates without properly accounting for the fundamental differences between growth-stage/Blockbuster IP and mature, declining-value legacy compounds, the IRS's arm's-length range would be skewed upward.
3.  Challenge to PPC's CUT selection criteria. The IRS may argue that PPC's CUT selection criteria are too narrow or that the comparability adjustments applied by Whitmore Valuation Group are insufficient. Specifically, the IRS may contend that PPC's focus on mature, declining-revenue products as the basis for CUT selection improperly excludes relevant comparables at higher rates.
If the IRS were to propose an 11.0% royalty rate, the resulting adjustment for the legacy IP royalty alone would be as follows:
A total proposed royalty adjustment of approximately $188.04 million across the four examination years represents a significant potential exposure for PPC and warrants a vigorous and well-prepared defense.
B. Rebuttal Arguments
We recommend the following rebuttal arguments in response to the anticipated IRS challenge:
1. CUT Comparability Deficiency in IRS Selections. Any CUT comparables selected by the IRS at an 11.0% royalty rate almost certainly involve growth-stage or blockbuster pharmaceutical compounds with fundamentally different risk/reward profiles than PPC's declining legacy compound portfolio. Growth-stage and blockbuster compounds typically exhibit strong revenue growth trajectories, significant remaining patent life, limited generic competition, and substantial profit potential. The legacy compounds, by contrast, are mature products with declining revenues, diminishing patent protection, increasing generic competition, and limited future growth potential. These differences are material to the comparability analysis and would render the IRS's higher-rate CUT selections unreliable under the comparability standards of Treas. Reg. § 1.482-4(c) and § 1.482-1(d).
We should prepare a detailed side-by-side comparison of PPC's 14 CUT comparables with any CUT comparables the IRS selects, highlighting the comparability deficiencies in the IRS's selections. This analysis should focus on product lifecycle stage, revenue trajectory, remaining patent life, competitive dynamics, and profit potential as key differentiating factors.
2. Product Lifecycle Stage. The product lifecycle stage of the legacy compounds is the single most important comparability factor in this analysis. The legacy compounds are mature, declining-revenue products that are approaching or have already passed the peak of their commercial potential. Higher-rate CUT comparables typically involve IP with significant growth potential, pipeline expansion value, or blockbuster status — characteristics that the legacy compound portfolio does not exhibit. A 4.5% royalty rate is entirely consistent with the arm's-length rates observed for mature pharmaceutical IP, while an 11.0% rate would be appropriate only for IP with substantially greater income-generating potential.
3. PBI's Functions and Risks. PBI performs substantial and meaningful commercialization functions in the non-Americas territory, including regulatory maintenance across 68 country markets (at a cumulative cost of €47.2 million over 2017–2020), independent pricing and commercial strategy, supply chain management, medical affairs, and distribution. PBI also employs 185 people and maintains significant operational infrastructure in Dublin. In comparable arm's-length transactions, a licensee that performs these functions and bears these risks would be entitled to retain a larger share of the profits from commercialization, which translates into a lower royalty rate payable to the licensor. The IRS's proposed increase in the royalty rate to 11.0% would not be consistent with the functional and risk profile of the PPC-PBI arrangement or with the rates observed in arm's-length transactions involving licensees with comparable functional profiles.
4. Arm's-Length Range Compliance. PPC's 4.5% royalty rate falls within the interquartile range of 3.1% to 6.8% established by 14 reliable CUT comparables. Under Treas. Reg. § 1.482-1(e)(2), no adjustment is warranted when the tested price falls within the arm's-length range. The IRS cannot simply propose an alternative rate without first establishing